May 2019

Column

Editor's Page

05/15/2019

Winston Wong, PharmD, Editor-in-Chief

Many oncology practices have adopted clinical pathways over the last 5 years with varying degrees of success. These mixed results may stem from a lack of understanding or full commitment from practices in terms of...

Many...

05/15/2019

Journal of Clinical Pathways

Clinical Pathways GPS

CMS Policies Concerning CAR T-Cell Therapy

05/15/2019

Matthew Pakizegee, PharmD, MS

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Chimeric antigen receptor (CAR) T-cell therapy is a new form of cancer therapy that uses a patient’s own immune system to fight the disease. This type of cell therapy uses an individualized process to develop a...

...

05/15/2019

Journal of Clinical Pathways

Pharma Insights

The Health Care Ecosystem and Social Determinants of Health: Surveys Suggest the Stage Is Set for Novel Collaborations

05/15/2019

Maureen Hennessey, PhD, CPCC, CPHQ

Larry Blandford, PharmD—Column Editor

Dr Hennessey relates her past personal experience with cancer care delivery when her mother was receiving chemotherapy for lung cancer, where an issue with care access could have significantly altered her mother’s...

Dr...

05/15/2019

Journal of Clinical Pathways

Department

Pathways in Practice

Current Therapies for Patients With Prostate Cancer: Managing Skeletal-Related Events

05/15/2019

JCP Editors

In this series, we speak with cancer care practitioners about how pathways are being used in their practices, how they are being applied in a particular disease state, and what challenges remain for treatment...

In...

05/15/2019

Journal of Clinical Pathways

Tools and Resources

Tools for Transformation

Achieving Organizational Culture Change in Your Practice to Support an Effective Pathways Program

05/15/2019

Gordon Kuntz—Column Editor

Gordon Kuntz is a health care consultant and strategic advisor with over 30 years’ experience in a multitude of health care settings, working with payers and providers, and in technology and strategy. He began his...

Gordon...

05/15/2019

Journal of Clinical Pathways

Feature

From the Field

The Supportive Care of Oncology Patients (SCOOP) Pathway: A Novel Approach to Improving the Patient Experience in the Curative Treatment of Cancer

05/15/2019

Christopher Koprowski, MD, MBA

Nicholas Petrelli, MD, FACS

Edith J Johnson, PhD, MBA

Karen Sites, MSN, RN, OCN

Abstract: It was hypothesized that by introducing more intense supportive care and enhanced nurse navigation in high-acuity curable cancer patients, we could achieve the same results noted in patients with advanced...

...

05/15/2019

Journal of Clinical Pathways

Perspectives

Value-Based Management of Clinical Pathways: An Applied Framework

05/15/2019

Christopher P Chen, MD, MBA

Leah M Marcotte, MD, FACP

Kimberley Herner, MD

Joshua M Liao, MD, MSc, FACP

Abstract: For health care organizations, clinical pathways have historically been important tools for translating medical evidence into practice and delivering high-quality, cost-conscious (ie, high-value) care....

...

05/15/2019

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

May 2019

Column

Department

Tools and Resources

Feature

Current Issue

Special Reports

Subscribe

Volume 5

Specialties

Events

Year Round Education

HMP Global Products